IN THE SPOTLIGHT

Understanding LUAD vs. LUSC in Lung Cancer Treatment

Understanding LUAD vs. LUSC in Lung Cancer Treatment

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China

Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC

Yüksel Ürün: Ivonescimab vs pembrolizumab in PD-L1 positive NSCLC

With tislelizumab, BeiGene brings immunotherapy to more patients in Europe

With tislelizumab, BeiGene brings immunotherapy to more patients in Europe

Sylvester Study Highlights Global Trends in Lung Cancer Risk Factors: Tobacco, Pollution, and Asbestos

Sylvester Study Highlights Global Trends in Lung Cancer Risk Factors: Tobacco, Pollution, and Asbestos

Yvonne Diaz on the hopes and concerns of cancer patients regarding the use of AI wearables – Lung Cancer Europe

Yvonne Diaz on the hopes and concerns of cancer patients regarding the use of AI wearables – Lung Cancer Europe

When should lung cancer be treated with immunotherapy?

When should lung cancer be treated with immunotherapy?

Ponsegromab Reduces Symptoms Linked to Cancer Cachexia, Elevated GDF-15

Ponsegromab Reduces Symptoms Linked to Cancer Cachexia, Elevated GDF-15

Low ctDNA Levels are Prognostic of Outcomes in Early-Stage Lung Adenocarcinoma

Low ctDNA Levels are Prognostic of Outcomes in Early-Stage Lung Adenocarcinoma